• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP=906853; DepMap=ACH-001494).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP=906853; DepMap=ACH-001494).
  

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=26956050; DOI=10.18632/oncotarget.7914; PMCID=PMC4991440
Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J., Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A., Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Oncotarget 7:20080-20092(2016)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451
Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S., Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D., Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.
RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.
Cancers (Basel) 12:2510.1-2510.14(2020)

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022)